advanced pancreatic cancer
About
Pancreatic cancer is known as the "king of cancers" and its early diagnosis rate is extremely low. Mutations in the KRAS gene have an incidence of more than 90% in pancreatic cancer and have been regarded as non-drug targets. Core dilemmas: ①KRAS was once regarded as a non-drug target, but only in recent years did a breakthrough occur;② Pancreatic cancer has a unique desmoplasia, which physically compresses tumor blood vessels, resulting in extremely poor blood flow perfusion and difficult for drugs to penetrate;③ A large number of immunosuppressive cells (Tleaves, MDSCs) in the tumor microenvironment hinder the efficacy of immunotherapy.
Features & Symptoms
- Very low early diagnosis rate
- Metastasis has occurred at the time of diagnosis
- Accompanied by severe abdominal pain, jaundice, weight loss
- Initially sensitive to chemotherapy but highly resistant
Treatment Options
| Treatment | Description | Stage | Price Range |
|---|---|---|---|
| KRAS G12C/G12D targeting drugs | A new generation of KRAS inhibitors (sotorasib, adagrasib) combined with immune checkpoint inhibitors has shown breakthrough efficacy in KRAS mutant pancreatic cancer. | Phase II/III | $120K - $400K/年 |
| mRNA tumor vaccine | Personalized mRNA vaccines based on new antigens (such as BioNTech's BNT122) are used in conjunction with PD-1 to activate specific anti-tumor immunity. | Phase II | $200K - $600K/疗程 |
| Oncolytic virus + immune combination | Genetically modified adenovirus or herpesvirus is injected directly into tumors, combined with PD-1/CTLA-4 inhibitors, breaking the immunosuppressive microenvironment. | Phase I/II | $150K - $450K/疗程 |
Prognosis
The median survival time is 6-8 months, and the 5-year survival rate is less than 10%
Additional Notes
Notes: Genetic testing recommendations: It is recommended to perform gene testing such as KRAS, BRCA1/2, PALB2, MSI/MMR. Patients with BRCA1/2 mutations can benefit from platinum-containing regimens and PARP inhibitors;BRCA mutation management: Patients with BRCA1/2 mutations can consider FOLFIRINOX regimen on the front line, and olapali can be used for maintenance treatment; Pain management: Pancreatic cancer pain is often severe, so it is recommended to adopt a WHO three-step analgesia regimen, and celiac plexus block is feasible if necessary; Nutritional support: Pancreatic exocrine dysfunction is common, and pancreatic enzymes and fat-soluble vitamins need to be supplemented; Biliary obstruction: If obstructive jaundice occurs, ERCP or PTCD drainage is required. Exclusive service commitment: The platform will allocate a dedicated medical team to each patient to assist in dismantling and properly deploying the following precautions throughout the process. When cross-state and cross-border diagnosis and treatment projects or drugs are involved, the platform will make overall arrangements for the entire docking; for disabled and semi-disabled patient groups, the platform will provide rush-free alternative solutions (including remote consultation, door-to-door sampling, direct drug delivery in the cold chain, etc.), to ensure that patients can get the same high-quality diagnosis and treatment resources without having to travel in person.; Study phase: Phase II/III clinical. Prognosis: The median survival time is 6-8 months, and the 5-year survival rate is less than 10%.
Frequently Asked Questions
What is advanced pancreatic cancer?
Pancreatic cancer is known as the "king of cancers" and its early diagnosis rate is extremely low. Mutations in the KRAS gene have an incidence of more than 90% in pancreatic cancer and have been regarded as non-drug targets. Core dilemmas: ①KRAS was once regarded as a non-drug target, but only in recent years did a breakthrough occur;② Pancreatic cancer has a unique desmoplasia, which physically compresses tumor blood vessels, resulting in extremely poor blood flow perfusion and difficult for drugs to penetrate;③ A large number of immunosuppressive cells (Tleaves, MDSCs) in the tumor microenvironment hinder the efficacy of immunotherapy.
What are the symptoms of advanced pancreatic cancer?
Very low early diagnosis rate,Metastasis has occurred at the time of diagnosis,Accompanied by severe abdominal pain, jaundice, weight loss,Initially sensitive to chemotherapy but highly resistant
How is advanced pancreatic cancer treated?
KRAS G12C/G12D targeting drugs: A new generation of KRAS inhibitors (sotorasib, adagrasib) combined with immune checkpoint inhibitors has shown breakthrough efficacy in KRAS mutant pancreatic cancer.; mRNA tumor vaccine: Personalized mRNA vaccines based on new antigens (such as BioNTech's BNT122) are used in conjunction with PD-1 to activate specific anti-tumor immunity.; Oncolytic virus + immune combination: Genetically modified adenovirus or herpesvirus is injected directly into tumors, combined with PD-1/CTLA-4 inhibitors, breaking the immunosuppressive microenvironment.
What is the prognosis for advanced pancreatic cancer?
The median survival time is 6-8 months, and the 5-year survival rate is less than 10%